Progress on geovax's universal coronavirus vaccine candidate, geo-cm02, presented at vaccines summit 2023

Single-dose protection demonstrated against multiple sars-cov-2 variants atlanta, ga, nov. 14, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of preclinical vaccine efficacy data for geo-cm02, a multi-antigen investigational sars-cov-2 vaccine. the data were presented during the vaccines summit 2023 conference, being held in boston, ma on november 13-15, 2023.
GOVX Ratings Summary
GOVX Quant Ranking